Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma.
Bagratuni T, Terpos E, Eleutherakis-Papaiakovou E, Kalapanida D, Gavriatopoulou M, Migkou M, Liacos CI, Tasidou A, Matsouka C, Mparmparousi D, Dimopoulos MA, Kastritis E. Bagratuni T, et al. Among authors: dimopoulos ma. Br J Haematol. 2016 Jan;172(1):44-7. doi: 10.1111/bjh.13786. Epub 2015 Nov 13. Br J Haematol. 2016. PMID: 26564000 Free article.
Thalidomide in the treatment of multiple myeloma.
Kastritis E, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Best Pract Res Clin Haematol. 2007 Dec;20(4):681-99. doi: 10.1016/j.beha.2007.09.001. Best Pract Res Clin Haematol. 2007. PMID: 18070713 Review.
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment.
Dimopoulos MA, Christoulas D, Roussou M, Kastritis E, Migkou M, Gavriatopoulou M, Matsouka C, Mparmparoussi D, Psimenou E, Grapsa I, Efstathiou E, Terpos E. Dimopoulos MA, et al. Eur J Haematol. 2010 Jul;85(1):1-5. doi: 10.1111/j.1600-0609.2010.01432.x. Epub 2010 Feb 20. Eur J Haematol. 2010. PMID: 20192988
High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients.
Kastritis E, Roussou M, Michael M, Gavriatopoulou M, Michalis E, Migkou M, Delimpasi S, Kyrtsonis MC, Gogos D, Liapis K, Charitaki E, Repousis P, Terpos E, Dimopoulos MA; Greek Myeloma Study Group. Kastritis E, et al. Among authors: dimopoulos ma. Br J Haematol. 2010 Sep;150(5):587-91. doi: 10.1111/j.1365-2141.2010.08288.x. Epub 2010 Jul 7. Br J Haematol. 2010. PMID: 20618328 Free article.
Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy.
Migkou M, Kastritis E, Roussou M, Gkotzamanidou M, Gavriatopoulou M, Nikitas N, Mparmparoussi D, Matsouka C, Gika D, Terpos E, Dimopoulos MA. Migkou M, et al. Among authors: dimopoulos ma. Eur J Haematol. 2011 Oct;87(4):323-9. doi: 10.1111/j.1600-0609.2011.01659.x. Epub 2011 Aug 26. Eur J Haematol. 2011. PMID: 21631590
Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents.
Tasidou A, Roussou M, Terpos E, Kastritis E, Gkotzamanidou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E, Nikitas N, Anagnostou D, Dimopoulos MA. Tasidou A, et al. Among authors: dimopoulos ma. Am J Hematol. 2012 Jul;87(7):734-6. doi: 10.1002/ajh.23223. Epub 2012 May 6. Am J Hematol. 2012. PMID: 22565393 Free article.
1,275 results